Last reviewed · How we verify
Methylphenidate Oral Product
Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.
Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Methylphenidate Oral Product |
|---|---|
| Also known as | Concerta, OROS-MPH, Central Nervous Systemt (CNS) stimulants |
| Sponsor | Vrije Universiteit Brussel |
| Drug class | Central nervous system stimulant; sympathomimetic amine |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters (DAT and NET) for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The drug is a central nervous system stimulant commonly used to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Tachycardia
- Abdominal pain
Key clinical trials
- Effects of Commonly Used Medications on Mood and Choice (PHASE1)
- Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue (PHASE3)
- Precision Functional Brain Mapping in Psilocybin (EARLY_PHASE1)
- Oxygen Toxicity: Mechanisms in Humans (NA)
- Targeting Drug Memories With Methylphenidate (EARLY_PHASE1)
- The Role of the Brain in Mental and Physical Fatigue (PHASE3)
- Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate) (PHASE1)
- The Role of Brain Dopamine in Chronic Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylphenidate Oral Product CI brief — competitive landscape report
- Methylphenidate Oral Product updates RSS · CI watch RSS
- Vrije Universiteit Brussel portfolio CI